ALT Medicenna news graphic on a dark purple ground with a 3D render of purple protein-like clusters. Label: "Biomarker enriched GI cancers · Clinical results." Headline: "40% ORR in tumors resistant to approved therapies." Numbers: 80% disease control rate (DCR; 16/20); 4/4 patients with liver metastasis had regression of all target liver lesions (8/8) with MDNA11 monotherapy. Line: "Responses were durable, with median duration of response (mDOR) not reached, and responses ongoing." Source: Phase 1/2 ABILITY-1, MDNA11 alone and in combination with pembrolizumab, 20 efficacy-evaluable patients, oral session at the SITC 2026 Annual Meeting. Ticker badge: TSX: MDNA | OTCQB: MDNAF.
ALT Medicenna graphic for an upcoming presentation at The Promises of Treg and Interleukin-2 Therapies conference in Paris, France. Headline: "One Target. Two Pathways." Text: "MDNA209 is designed to block CD122 and inhibit IL-2 and IL-15." Friday, October 23, 4:30 p.m. CEST, presented by Dr. Minh D. To. TSX: MDNA | OTCQB: MDNAF. A 3D render of purple protein clusters fills the right side.
ALT A title slide featuring the Medicenna and Fondazione Melanoma Onlus logos. The main headline reads "The Science of Timing" with a sub-headline "Why we are moving MDNA11 to the front lines of Melanoma care".
ALT https://ir.medicenna.com/news-releases/news-release-details/medicenna-and-fondazione-melanoma-onlus-announce-first-patient
ALT Corporate announcement graphic from Medicenna featuring a smiling headshot of Dr. Nageatte Ibrahim set against a deep purple, scientific cellular background. Bold white text reads: 'Dr. Nageatte Ibrahim, Appointed Chief Medical Officer.' The Medicenna logo sits in the top left corner, and the company's stock tickers, TSX: MDNA | OTCQX: MDNAF, are displayed in the bottom right
ALT A text graphic with a dark cellular background. The text reads: Momentum in Immuno-Oncology. Strategic Signals in PD-1 Bispecifics. Greater than $43 Billion in recent combined transaction value." The Medicenna logo and #AACR26 hashtag are in the bottom corners.
ALT A graphic with a deep purple background featuring the Medicenna logo and tickers TSX: MDNA and OTCQX: MDNAF at the top. The main text reads "Spring 2026 Conference Roadmap." On the right side is a detailed 3D illustration of a purple molecular structure. Small text at the bottom reads "Swipe to see upcoming events
ALT A presentation slide with a purple background detailing the 7th Annual Glioblastoma Development Summit. Date: February 19, 2026, in Boston, MA. Format: Presentation and Panel Discussions at 10:00 AM EST. Presenter: Dr. Fahar Merchant, President and CEO. The presentation topic is "Surmounting Barriers in Non-resectable Recurrent Glioblastoma with Bizaxofusp.